In a Phase III trial, an ocular therapeutic product, EGP-437, being developed by EyeGate Pharma Inc., of Waltham, Mass., was noninferior to prednisolone acetate 1 percent ophthalmic suspension for anterior uveitis. EGP-437 comprises a formulation of dexamethasone delivered into the eye using an ocular iontophoresis device.